Oncolytic viruses (OV) represent antitumor effects in the ways of direct tumor lysis and by stimulating host tumor immunity, but maximum therapeutic effect of OV requires proper delivery into the tumor beds. Stem and immune cells are promising cellular vehicles for this OV delivery. However, there is a problem to this strategy: the OV will replicate and lyse within the carrier cell, meaning that the carrier cell has to be delivered to the host and reach the tumor to disperse the OV. We have engineered a doublevector system, where a replication-defective adenovirus can be switched to become oncolytic in the presence of Flp recombinase expressed by a replication-defective amplicon under tight transcriptional control of tumor hypoxia-regulatable elements. Human mesenchymal stem cells, infected with both vectors, remain viable for prolonged periods of time and do not generate OV under normoxic conditions, but placed under hypoxic conditions they will lyse and generate OVs.
Abstract:
Oncolytic viruses (OV) represent antitumor effects in the ways of direct tumor lysis and by stimulating host tumor immunity, but maximum therapeutic effect of OV requires proper delivery into the tumor beds. Stem and immune cells are promising cellular vehicles for this OV delivery. However, there is a problem to this strategy: the OV will replicate and lyse within the carrier cell, meaning that the carrier cell has to be delivered to the host and reach the tumor to disperse the OV. We have engineered a doublevector system, where a replication-defective adenovirus can be switched to become oncolytic in the presence of Flp recombinase expressed by a replication-defective amplicon under tight transcriptional control of tumor hypoxia-regulatable elements. Human mesenchymal stem cells, infected with both vectors, remain viable for prolonged periods of time and do not generate OV under normoxic conditions, but placed under hypoxic conditions they will lyse and generate OVs.
This strategy enables viral carrier cells to survive for a longer period of time than cells carrying general OVs. As a result, treatment with preinfected human mesenchymal stem cells extended the survival of human glioma-bearing mice.
Our results indicate that a balance of viability and the function of carrier cells can be achieved using hypoxia-elicited oncolytic conversion of replication-defective adenovirus and contribute to the therapeutic success of orthotopic glioma. *** Title: Can Neurostimulation Replace Narcotics?
Author: Joseph W. Boggs, PhD SPR Therapeutics Abstract: SPR Therapeutics has developed a first-of-its kind percutaneous peripheral nerve stimulation (PNS) therapy for the management of chronic and acute pain. The proprietary PNS lead is delivered using a small, 20-gauge introducer needle, typically under ultrasound guidance. The externalized lead is connected to the SPRINT external pulse generator. To date, no infections have been observed in > 300 patients with peripheral pain implanted up to 60 days. The lead is nonsurgically removed at the end of the 60-day implant period. The PNS has conventionally been indicated in management of chronic neuropathic pain, of which postamputation pain is among the most difficult to treat. SPR has demonstrated reduced pain and pain interference in this population by approximately 80 %, noting carry-over pain relief for several weeks following lead removal. Cost and invasiveness have limited the use of PNS and relegated it to a treatment of last resort, but that may be changing. According to a blinded survey of 62 interventional pain specialists, > 60 % would plan to use percutaneous PNS in place of opioids, a first-line therapy, when available. The minimally invasive, reversible approach is also being evaluated in the management of acute pain following total knee arthroplasty. Clinical trials now underway may prove the utility of PNS in this large group of patients previously relegated to opiates postdischarge. Approximately 800,000 total knee arthroplastys are performed in the USA, representing a large and growing group of patients who may benefit from this therapy.
While the above therapies address pain by generating paresthesia, SPR Therapeutic's platform can be configured to evoke motor contractions in the management of musculoskeletal pain. Average reductions in pain of nearly 70 % and sustained relief to 12 months and beyond have been published in SPR Therapeutic's first targeted indication: poststroke shoulder pain. Feasibility trials are now underway, translating these approaches to care for patients with chronic lower back pain. SPR Therapeutics has received nearly $14 M in federal grants and approximately $10 M in equity investments to date. *** Title: Biopolymer Device to Stop Bleeding During Brain Surgery Author: Richard Russo, MBA Endomedix, Inc.
Control of bleeding is a challenge in intracranial surgery. Twenty to 25 % of the length of a typical procedure is expended controlling bleeding, with 7-10 intraoperative incidents requiring hemostasis. The procedure is paused while hemostasis is achieved in each incident. While electrocautery is effective and quick when bleeders can be visualized and isolated, the oozing flow from bleeders that cannot be visualized can be difficult and time consuming to control. Additionally, swelling resulting from the use of available hemostats is dangerous as noted in Food and Drug Administration-approved instructions for use, and many products in use have not be tested or cleared for this indication. A patented technology using processed biopolymers (polysaccharides) has been developed. Two biopolymers are processed separately and placed in separate aqueous solutions. No cross-linking agent is utilized. The 2 solutions are designed to be simultaneously mixed and sprayed onto bleeding sites during surgery. These form hydrogel devices in situ within seconds. The hydrogel is conformable, adherent, transparent, and pliable but strong. The hydrogel functions as a passive hemostat (mechanical clot) to staunch bleeding; a second generation to provide active hemostasis without the addition of biological components is in development. The hydrogel devices degrade enzymatically over time (weeks), and are expected to be excreted through the kidneys or utilized as a food source. Prototype samples have been tested for cytotoxicity and passed. In vitro testing using ASTM standard test method F2392-04 in a validated test apparatus has demonstrated that the current prototypes are 15× and 2.8× stronger than fibrin glue and fibrinogen/thrombin products, respectively, and also stronger than a synthetic polymer device. A controlled in vivo test (porcine liver model) demonstrated the mean time to hemostasis with the Endomedix prototypes was 29 s. None of the controls (standard of care: Gelfoam dressing soaked in thrombin, maintained with standard pressure) achieved hemostasis in < 4 min. The project has completed the specification of the starting materials, processing parameters, and controls (e.g., in situ Fourier transform infrared spectroscopy, etc.). We are in the process of scale up and starting biocompatibility (ISO 10993) and stability testing. *** Title: The Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders Author: Michael Detke, MD, PhD Embera NeuroTherapeutics and Indiana University
No pharmaceutical treatments are currently available for cocaine use disorder, and treatments for tobacco use disorder are effective 25 % of the time, at best. EMB-001 is a combination of 2 Food and Drug Administration-approved drugs: metyrapone (a cortisol synthesis inhibitor) and oxazepam (a benzodiazepine). Metyrapone is approved for 1 day only as a test; oxazepam is approved for acute and chronic treatment of anxiety. We hypothesized that a combination of drugs working by different stress-related mechanisms may be efficacious for the treatment of substance use disorders, at doses that minimize the safety/tolerability risks of each individual drug. We summarize preclinical and clinical data supporting the potential efficacy and safety of EMB-001 for the treatment of substance use disorders, including a pilot human study in cocaine-dependent patients, and a recently completed phase I combined single/multiple ascending dose safety and pharmacokinetic (PK) study. EMB-001 reduced cocaine self-administration in rats at doses of each individual drug that were ineffective alone. EMB-001 also reduced nicotine self-administration in rats, and attenuated cocaine and methamphetamine cue reactivity in rats. A pilot human study of EMB-001 in cocaine dependence showed a significant reduction in cocaine use and EMB-001 was generally well tolerated. A new phase I safety and PK study revealed EMB-001 to be well tolerated with no new safety signals identified. These safety results are generally consistent with 5 other published studies. PK results from this new study suggest twice-daily dosing may provide appropriate duration of exposure for efficacy. EMB-001 is effective in several animal models of drug addiction. A pilot human study suggested efficacy in cocaine-dependent patients, and good tolerability. New data from a phase I study extend the safety and tolerability findings, and PK support twicedaily dosing. EMB-001 has the potential to treat cocaine and methamphetamine use disorders, for which no Food and Drug Administration-approved treatments exist. It also has potential for tobacco use disorder, for which a large unmet need and limited treatment options exist. Proposed reasons for these failures include the timing of treatment after insult, off-target effects, and a failure to reach efficacious dose levels at the site of injury. NP10679 is a highly selective, pH-dependent inhibitor of the GluN2B subtype of the NMDAR with negligible activity at the other NMDAR subtypes. In vitro, NP10679 is approximately 6.2-fold more potent at pH 6.9 than at pH 7.6. The pH dependence increases the selectivity and potency of the compound under conditions of lower pH, such as that of ischemic brain tissue, thereby improving safety and tolerability. NP10679 mitigates functional impairment in a mouse model of SAH and limits the extent of neurodegeneration in mouse middle cerebral artery occlusion model of stroke. The beneficial effects of NP10679 in the SAH model are long lasting, with functional improvement observed up to 28 days. The results of preinvestigational new drug toxicity studies conducted with NP10679 suggest that it can be safely administered to humans in the proposed first clinical trial. The selectivity and specificity of NP10679 will allow for prophylactic use in patients at risk for an ischemic event. This is significant as a wide range of data suggests that the best opportunity for neuroprotection occurs when NMDAR blockers are administered prior to the ischemic insult. NP10679 administered at the time of "clipping" surgery in SAH offers optimal timing for intervention as ischemic events in SAH are due to vasospasms that occur 3-14 days after hemorrhage. We would like to acknowledge the financial support of the National Institute of Neurological Diseases and Stroke (NINDS) to support this work. 2 -methyl-5 ± -pregnan-20-one), which is a central nervous system-selective γ-aminobutryic acid A (GABA A ) modulator and a synthetic a n a l o g o f a l l o p r e g n a n o l o n e . T h e e f f e c t s o f allopregnanolone have been studied for > 2 decades and its role in controlling seizures and improving anxiety, mood, and sleep through positive modulation of GABA A receptors is well documented. Ganaxolone was designed to have the same GABA modulation effects at the GABA A receptors as allopregnanolone without activation of nuclear (classical) progesterone receptors. Ganaxolone and allopregnanolone differ from other GABA agents by interacting with both the synaptic and extrasynaptic GABA A receptors and at a binding site distinct from benzodiazepines. Seizure protection has been demonstrated with ganaxolone in a broad range of animal seizure models, and unlike other GABA A receptor modulators, ganaxolone does not show tolerance to anticonvulsant activity with chronic administration. Ganaxolone is being developed as adjunctive therapy for the treatment of focal onset seizures in adults, as well as in 2 orphan pediatric programs (PCDH19 Pediatric Epilepsy and Behaviors in Fragile X). In adult epilepsy, we have completed a phase II clinical trial in 147 patients with focal-onset seizures demonstrating that patients who added ganaxolone to their medication regimen experienced a statistically significant reduction in seizures compared with patients who added placebo. We are currently conducting a double-blind, randomized phase III clinical trial with ganaxolone using a twice-daily capsule formulation at doses up to 1800 mg/day in patients with drug-resistant focal-onset seizures. We have recently developed an intravenous formulation of ganaxolone. This formulation has been tested in Good Clinical Practice preclinical toxicology studies and found to be safe and well tolerated. In preclinical models of diazepam-resistant status epilepticus, intravenous administration of ganaxolone produced a sustained reversal (>5 h) of epileptic activity and promoted survival comparison with animals that received vehicle. We are planning to commence phase I development of intravenous ganaxolone for treatment of status epilepticus. Abstract: L-Dopa-induced dyskinesia (LID) is a common and disabling complication of chronic L-dopa therapy, and its medical management continues to be a major unmet need in patients with Parkinson disease (PD). Changes in opioid transmission in the basal ganglia associated with LID suggest a therapeutic opportunity. However, a complex pharmacological profile may be necessary for therapeutic activity, as prior attempts using nonselective or selective opioid agents have yielded inconsistent and suboptimal efficacy. The totality of the evidence from preclinical and clinical studies suggests that the combination of stimulating k opioid transmission and inhibiting μ opioid transmission is needed for effective anti-LID activity. We have determined the impact of modulating both these opioid receptor signals using the mixed k agonist/μ antagonist analgesic nalbuphine in reducing LID in a nonhuman primate model. Cynomolgus macaques were rendered parkinsonian by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration and treated with oral L-dopa/carbidopa (Sinemet 100/ 25 mg) daily to induce the development of dyskinesias. Animals with advanced stable parkinsonism and reproducible LID received a range of nalbuphine doses or saline subcutaneously as 1) monotherapy, 2) acute co-administration with Ldopa, and 3) chronic co-administration for a month. Animals were assessed by blinded examiners for motor disability and LID severity using standardized rating scales. We found that nalbuphine reduced LID in a dose-dependent manner by nearly 50 % (p < 0.001) without compromising the antiparkinson effect of L-dopa or changing plasma L-dopa levels. There was no tolerance to the anti-LID effect of nalbuphine given chronically. Nalbuphine co-administered with L-dopa was well tolerated and did not cause sedation or other adverse effects. Nalbuphine monotherapy had no effect on motor disability. Analysis of brains using Western blotting showed that nalbuphine co-therapy blocks several molecular correlates of LID in the striatum, including overexpression of prodynorphin, dynorphin A, and Delta-FosB, as well as associated signaling kinases. We conclude that nalbuphine is a safe and effective anti-LID agent, and our findings support its efficient advancement to clinical testing in patients with PD with LID. 
Therapeutic hypothermia (TH) is the first intervention to reduce brain injury in term infants after hypoxic-ischemic encephalopathy, but protection is incomplete, thus driving the need for combination therapies. We hypothesized that delayed administration of N-acetyl-cysteine (NAC) conjugated to nanoparticle dendrimers at the end of hypothermia would provide additional protection over TH alone. The anti-inflammatory drug NAC has poor bioavailability, which limits efficacy for brain injury. In contrast, NAC conjugated to hydroxyl-terminated poly (amidoamine) dendrimer nanoparticles (D-NAC) can cross the impaired blood-brain barrier in some models of brain injury, allowing for the selective accumulation and release of nanoparticle-conjugated NAC within activated microglia, astrocytes, and injured neurons. Kannan et al. (Sci Transl Med 2012; 4:130) have previously shown that NAC conjugated to dendrimer nanoparticles leads to significant improvement in motor deficits and the phenotype of cerebral palsy when delivered systemically to newborn rabbits with cerbral palsy following exposure to intrauterine inflammation. Oxidative injury and inflammation are known to play important roles in the pathophysiology of brain injury following hypoxic-ischemic encephalopathy. These processes may be mediated by activated microglia and astrocytes. We used a mouse model of carotid ligation at postnatal day (P)5 (to mimic ischemic insult in very preterm infants) and a near-term model of neonatal hypoxic ischemia at P7 (hypoxic ischemia carotid ligation followed by hypoxia) to evaluate the neuroprotective efficacy of D-NAC using measurement of inflammatory cytokines and semiquantitative histopathology. In the P5 model, D-NAC was administered 24 h or 5 days after the injury and brains were evaluated on P14. For the P7 model, D-NAC-Cy5 (D-NAC + fluorescent dye Cy5) was administered with or without hypothermia. D-NAC-Cy5 was administered either at the beginning of hypothermia (0 h), at the time of rewarming (6 h), or 24 h after rewarming; uptake was evaluated 24 h later. In both models, dendrimer was taken up by activated microglia and astrocytes but was not seen in healthy, age-matched controls. Both subacute treatment at 24 h and delayed treatment at 5 days postinsult led to significant suppression of proinflammatory cytokines and improved myelination. In the near-term model, the extent of uptake in microglia, astrocytes, and neurons was correlated with the extent of injury and was comparable in normothermic and hypothermic animals. Delayed administration of D-NAC after TH reduced inflammatory cytokines and improved histopathology over hypothermia alone. D-NAC administration may not only be effective as a combination therapy with hypothermia, but may also be helpful in infants who are not candidates for hypothermia, such as extremely premature babies. The finding that uptake of D-NAC is proportional to injury and effective when given at the end of rewarming could be advantageous in a clinical setting in which injury can be assessed using magnetic resonance imaging. 
Muscle cramps can be painful and debilitating for those suffering from nocturnal leg cramps (NLC), multiple sclerosis, amyotrophic lateral sclerosis, and other neurological diseases. Although it is considered a benign condition, NLC can cause severe pain, interrupted sleep, and reduced quality of life, as well as interfere with activities of daily living. We have shown that a mixture of natural products containing transient receptor potential (TRP)V1 and TRPA1 channel activators suppresses electrically induced cramps (EIC) in healthy adults compared with a vehicle control. Based on known properties of neuronal circuits, we hypothesized that activation of TRP channels in the oral mucosa generates excitatory input via cranial nerve afferents; in turn, this activation increases the inhibitory tone of spinal interneurons to dampen motor neuron hyperexcitability in response to EIC. We call this process "chemical neurostimulation". We identified highly pure, synthetic TRP activators (FLX-787 and FLX-788) that were more effective than naturally occurring TRP activators in preventing EIC in healthy adults. We have now tested whether this EIC model translates to a clinical cramp setting in an exploratory efficacy study in NLC using our natural-product TRP activators.
Muscle cramping of the flexor hallucis brevis muscle was elicited through external stimulation of the abductor hallucis brevis muscle and medial plantar nerve in healthy normal volunteers. The intensity and duration of the cramp was recorded by surface electromyography for each patient in singleblinded, fixed-sequence, crossover studies. The recently completed NLC study was a randomized, controlled, crossover in 51 patients who experienced NLC at least 3 nights per week. FLX-787 and FLX-788 prevented or reduced cramp intensity in the human experimental cramp model (statistically significant, several-fold reduction in integrated area under the curve of the electromyography signal vs vehicle control). Compared with natural TRP activators, the anticramping effect of FLX-787 and FLX-788 was significantly enhanced. Preliminary results of the NLC study will also be presented. The results suggest that chemical neurostimulation through synthetic TRP activators is effective in the EIC model and may lead to new treatments for individuals suffering from cramps and spasticity associated with neurological disease. 
Spinal cord injury (SCI) results from motor vehicle accidents, falls, or sports-related injuries. At the cellular level, mild contusion to the spinal cord causes massive neuronal and glial cell loss, demyelination, cavitation, and glial scarring. These pathological changes result in loss of sensory perception, distal motor paralysis, and severe functional impairment. There is no cure for SCI; however, functional improvement depends on the success of a combination of molecular, cellular, and rehabilitative regenerative physiotherapies. Currently, there is a lack of universal methods or devices for isolation of cells or growth factors from any biological fluids such as bone marrow, cord blood, and liposuction for use in regeneration studies. We have developed a closed-device system, consisting of sterile, single-use disposable sets of isolation materials, that allow us to separate cells, while they are in 3-dimensional culture, and transfer them or their biological products in a functionally closed system to the sites of injury. Our good manufacturing practice-grade closed-system is used for isolation of minimally manipulated cells, conditioned media, trophic factors, exosomes, and microvesicles, and storage or delivery of these biological materials for regenerative applications. We validated this concept in studies of cellular therapy for canine and human patients with SCI. We reported the preclinical studies revealing that transplanted cells homed to the injury site, and resulted in spared white and gray matter, with remyelination, neural regeneration, functional improvement, and importantly, with no side effects observed. This led us to initiate an international randomized controlled phase I/II trial in humans, including 70 patients with chronic SCI. Data from the published registered trial demonstrated that 46 % of treated patients had increased motor scores by 10 points, with a number of patients regaining mobility. The preclinical and clinical studies together validate our model that minimally manipulated 3 dimensional-cultured cells and their products are capable of inducing significant repair, with a superior safety profile relative to other cell-therapy strategies derived from iPS or embryonic stem cells. Harnessing the full regenerative powers of autologous cells and their biological products could be further achieved with our device that allows the complete standardization of cell preparation, handling, and cell-therapy procedures. Acute exposure to nerve agents induces severe and prolonged status epilepticus (SE), which can be lethal or cause profound brain damage. The scientific community is actively seeking to develop antidotes to nerve agent-induced SE, which 1) will terminate ongoing SE in a timely manner, 2) will have a lasting effect so that seizures do not return after the initial termination of SE, 3) are effective anticonvulsants, even if administered with a significant delay after exposure to the nerve agent, 4) protect the brain against neuropathology, and 5) have no significant side effects. Our research efforts have resulted in the identification of a compound that fulfills the above requirements. LY293558 (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid) is an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/ GluK1 receptor antagonist that stops SE induced by soman exposure, in rats, within 20 min, significantly reduces the total duration of SE within 24 h of the exposure, and prevents neuronal loss and degeneration in all brain regions examined. In the basolateral amygdala, a region that plays a central role in seizure initiation after nerve agent exposure, LY293558 treatment prevents soman-induced decrease in the ratio of γ-aminobutyric acid-ergic interneurons to the total number of neurons; this is accompanied by prevention of the long-term increase in anxiety-like behavior. In 21-day-old rats, LY293558 treatment prevents the soman-induced, long-term reduction in amygdala and hippocampal volumes. LY293558 produces its beneficial effects even if administered 1 h after soman exposure. Pharmacokinetic studies have shown that LY293558 readily crosses the blood-brain barrier, and remains detectable in the blood for 8 h. Toxicity studies attested to the safety of LY293558 when used at the anticonvulsant and neuroprotectant doses. A specific GluK1 receptor antagonist, UBP302 [(S)-3-(2-carboxybenzyl)willardiine], has similar antidotal effects to those of LY293558 but displays a slower time course of action. In comparison to diazepam, both GluK1 antagonists are far superior; although diazepam efficiently terminates the initial SE induced by soman, it does not reduce the total duration of SE within 24 h, and does not protect against neuronal damage or the development of anxiety. These results suggest that antiglutamatergic agents are more promising anticonvulsants and neuroprotectants against nerve agents than anticonvulsants aimed at increasing inhibitory activity. 
Previous studies have demonstrated that inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX2)-mediated oxidant stress may represent a therapeutic target to brain injury following cerebral ischemia/reperfusion. Scutellarin is the major active component isolated from the Chinese herb Erigeron breviscapus (vant.) Hand. Mazz in the treatment of ischemic cerebrovascular diseases in the Far East. This study is aimed at elucidating if scutellarin has neuroprotective effects against an oxygen glucose deprivation (OGD)/reperfusion (OGD/R)-induced astrocyte injury that is linked to NOX2 expression in vitro.
Astrocytes were treated with OGD followed by reoxygenation. Immunofluorescence was used to check the purity of cultured astrocytes and cell viability was assessed with a cell counting kit-8 assay. To explore the potential mechanism of scutellarin, a molecular docking study was used to investigate the interaction between scutellarin and NOX2, and the expression of NOX2 was investigated by Western blotting. To verify the effect of the relationship between neuroprotection and the NOX2 gene, a NOX2 inhibitor (apocynin) was employed to observe the effects of NOX2 expression on the OGD/R treatment. Cell viability assays showed that scutellarin treatment significantly protected primary astrocytes from OGD/R-induced cell injury. The molecular docking study revealed that scutellarin and NOX2 could be effectively docked and the forms of active pocket were fitted well between them. Western blotting showed that scutellarin, as well as apocynin, treatment significantly decreased NOX2 expression in OGD/ R-induced NOX2 upregulation in astrocytes. The significance of our work is that we may provide a novel cellular approach as a combined therapy with thrombolysis for the treatment of ischemic stroke by demonstrating the unique protective action of scutellarin in astrocytes.
In conclusion, our study confirmed that scutellarin had neuroprotective effects against hypoxia-ischemia injury induced by OGD/ R in astrocytes through inhibiting the expression of NOX2. Abstract: Impairment in cognitive functioning and motor activity are commonly encountered in patients affected by multiple sclerosis (MS). The objective was to investigate the effect of enhanced environment on cuprizone mouse model of demyelination.
C57BL/6 male mice were divided into cuprizone only (Cup-O), cuprizone housed in environmental enhancement (Cup-EE), and control groups (9-10/group). Environmental enhancement continued for a period of 9 weeks. Neurobehavioral tests were conducted after a 6-week period of a 0.2 % cuprizone-enriched diet. All mice were assessed for cognitive performance in the 
Depression is a common disabling symptom of multiple sclerosis (MS), with a lifetime prevalence of 50 %. The aim of this study is to investigate the impact of induced depression on a cuprizone mouse model of demyelination. Mice were divided into cuprizone with no intervention (Cup-O), cuprizone undergoing induced depression (Cup-Dep), and control groups (9-10/group). Depression was induced by repeated open-space forced swim and was implemented 6 days prior to the testing period. MS was induced by continously feeding 6-week-old C57BL/6 male mice a 0.2 % cuprizone-enriched diet.
Spatial learning and memory were tested using the Morris water maze, while rotarod was used to assess motor function. 
Stroke is the leading cause of functional disability and gait problems. The purpose of this study was to determine the effect of rhythmic auditory stimulation combined with treadmill training on step length (on both affected and nonaffected sides) in stroke patients. Thirty male stroke patients participated in this study. The patients were assigned randomly into 2 equal groups, (study and control). Patients in the study group received treadmill training combined with rhythmic auditory stimulation in addition to selected physical therapy program for hemiparetic patients. Patients in the control group received treadmill training in addition to the same selected physical therapy program, including strengthening, stretching, weight bearing, balance exercises, and gait training. Biodex gait trainer 2 TM was used to assess step length (on both affected and nonaffected sides) before and after a 6-weeks training period (end of treatment) for both groups. There was a statistical significant increase in step length (on affected and nonaffected sides) in both groups post-treatment. The improvement in step length post-treatment was significantly higher in the study group compared with the control. Rhythmic auditory stimulation combined with treadmill training is effective in improving step length in patients with stroke when added to the selected physical therapy program. 
Effective pain relief with spinal cord stimulation (SCS) has historically been linked with paresthesias overlapping chronically painful areas. However, recent innovation has introduced paresthesia-free 10-kHz stimulation (HF10 therapy), shifting focus to improved patient outcomes. Twelve-month results comparing the 2 therapies have been reported elsewhere. This study compared HF10 therapy with traditional low-frequency (~50-Hz) SCS for the treatment of chronic back and leg pain, with 24-month efficacy outcomes reported. A randomized, controlled, pivotal trial was conducted across 11 comprehensive pain treatment centers. Patients had visual analog scale scores of e5.0 of 10.0 cm for both back and leg pain. Patients were randomly assigned (1:1) to receive HF10 therapy or traditional low-frequency SCS. The primary end point was responder rate, defined as e50% pain reduction.
In total, 198 patients were randomized to receive a short-term trial SCS system (101 HF10 therapy, 97 traditional SCS). In total, 171 patients (90 HF10 therapy, 81 traditional SCS) successfully completed the trial and were implanted. Patients averaged 54.9 ± 12.9 years of age, 13.6 ± 11.3 years since diagnosis, and 86.6 % had previous back surgery. At 24 months, back pain decreased to a greater degree with HF10 therapy [7.5 ± 1.3 cm at baseline to 2.4 ± 2.3 cm (66.9 %)] than traditional SCS [7.8 ± 1.2 cm at baseline to 4.5 cm ± .9 cm [AQ1] (41.1 %); p < 0.001]. Similarly, leg pain decreased to a greater degree with HF10 therapy [7.1 ± 1.5 cm at baseline to 2.4 ± 2.3 cm (65.1 %)] than traditional SCS [7.6 ± 1.4 cm at baseline to 3.9 ± 2.8 cm (46.0 %); p = 0.002]. More patients were responders to HF10 therapy than traditional SCS [back pain: 76.5 % vs 49.3 % (p < 0.001); leg pain: 72.9 % vs 49.3 % (p < 0.001)]. This study demonstrates the long-term superiority of HF10 therapy over traditional SCS in treating both back and leg pain. The advantages of HF10 therapy are anticipated to improve substantially the management of patients with chronic pain. 
Challenges in achieving adequate and stable paresthesia coverage in the axial back has limited the application of spinal cord stimulation (SCS) mostly to patients with predominant leg pain (North RB, et al. Neurosurg 1993; Kumar K, et al. J Neurosurg 1991; Oakley JC. Pain Med 2006; Kumar K, et al. Pain 2007) . Highfrequency (10-kHz), paresthesia-free SCS has demonstrated superior pain relief to traditional low-frequency (~50-Hz) SCS in a randomized controlled trial (Kapural L, et al. Anesthesiol 2015) . We compare 12-month study results from predominant back and predominant leg pain cohorts. Patients with both back and leg pain (e 5.0 cm in visual analog scale) were enrolled and randomly assigned to receive either test (HF10 therapy) or control (traditional SCS). Anatomic location with the higher VAS at baseline was deemed as predominant region of pain. A responder was defined as someone with an e50% reduction in VAS from baseline. A Mantel-Haenszel analysis was used to estimate the common odds ratio, and an exact Zelen test was used to assess the homogeneity of the odds ratios (ORs) across anatomical regions. In total, 198 subjects were randomized (101 test, 97 control) in the study, of whom 171 (90 test, 81 control) successfully completed a short-term trial and received an implant. Twelvemonth results for the defined cohorts are summarized as follows. 1) Predominant back pain (PBP), n = 52 (test), n = 42 (control). 
The multifaceted function of angiotensin II receptor antagonist (ARB), especially anti-inflammatory activity with the ability to promot nerve fiber regeneration, has potential for developing a new therapeutic strategy in neurology. We have investigated the effect of ARB, i.e. losartan, candesartan, and irbesartan (IRB), on experimental autoimmune neuritis (EAN) in Lewis rats. A synthetic peptide of 26 amino acids (aa 53-78) of bovine P2 protein was injected subcutaneously with complete Freund's adjuvant to induce EAN. Because of the large scale of the entire experiment, 3 experiments were done. In each of the experiments, 50 rats were divided into 2 groups and received ARB or vehicle (carboxyl methylcellulose) using a gastric tube daily from 2 days postimmunization through 26 days postimmunization. The doses of ARB were losartan 30 mg/kg, candesartan 10 mg/kg, and IRB 10 mg/kg. Rats were checked daily for motor impairment. Cauda equina from the rats 26 days postimmunization were fixed by 10 % buffered formalin, embedded in paraffin and examined for S-100 or CD68 immunoreactivity. Cauda equina, collected at baseline, presymptomatic, disease onset, peak, and recovery stages (n = 5 at each time point) from ARB-treated and CMC [AQ1]-treated rats were served for cytokine mRNA expression investigation using real-time polymerase chain reaction or quantitative competitive polymerase chain reaction. This experiment was approved by the Toho University Animal Experiment Committee (12-55-84, 11-54-84, 10-53-84, 13-51-215 , ARC/TUSM-R-16-6). All rats developed EAN at 11 days postimmunization. Motor symptoms peaked at 14-16 days postimmunization, and improved spontaneously thereafter. IRB-treated rats have a significantly mild clinical course and pathological changes compared with the other 2 ARB-treated groups. This suppression coincided with suppression of interferon-gamma mRNA expression and, reciprocally, upregulation of interleukin-10 mRNA expression in the active disease stage. ARB may suppress EAN, presumably by shifting the cytokine balance towards T helper type 2 cell dominancy. CCR2b antagonism, which is unique for IRB, may accentuate IRB superiority in suppression of EAN. IRB can be a therapeutic option for human Guillain-Barré syndrome, although its effect against other receptors (vitamin D receptor) that may influence the immune system remains unclear. 
Objectives: Muscle cramps can be painful and debilitating for those suffering from nocturnal leg cramps (NLC), multiple sclerosis, amyotrophic lateral sclerosis, and other neurological diseases. Although it is considered a benign condition, NLC can cause severe pain, interrupted sleep, and reduced quality of life, as well as interfere with activities of daily living. We have shown that a mixture of natural products containing transient receptor potential TRPV1 and TRPA1 channel activators suppresses electrically-induced cramps (EIC) in healthy adults compared to a vehicle control. Based on known properties of neuronal circuits, we hypothesized that activation of TRP channels in the oral mucosa generates excitatory input via cranial nerve afferents; this activation in turn increases inhibitory tone of spinal interneurons to dampen ± -motor neuron hyperexcitability in response to EIC. We call this process Chemical Neuro Stimulation. We identified highly pure, synthetic TRP activators ) that were more effective than naturally-occurring TRP activators in preventing EIC in healthy adult subjects. We have now tested whether this EIC model translates to a clinical cramp setting in an exploratory efficacy study in NLC using our natural product TRP activators.
Methods: Muscle cramping of the flexor hallucis brevis muscle was elicited through external stimulation of the abductor hallucis brevis muscle and medial plantar nerve in healthy normal volunteers. The intensity and duration of the cramp was recorded by surface EMG for each subject in single blinded, fixed-sequence, crossover studies. The recently completed NLC study was a randomized, controlled, crossover in 51 subjects who experienced NLC at least three nights per week.
Results: FLX-787 & FLX-788 prevented or reduced cramp intensity in the human experimental cramp model (statistically significant, several fold reduction in integrated AUC of the EMG signal vs. vehicle control). Compared to natural TRP activators, the anti-cramping effect of FLX-787 and FLX-788 was significantly enhanced. Preliminary results of the NLC study will also be presented.
Conclusion:
The results suggest that Chemical Neuro Stimulation through synthetic TRP activators is effective in the EIC model and may lead to new treatments for individuals suffering from cramps and spasticity associated with neurological disease. *** Title: The Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders Authors: Michael Detke, MD, PhD; Carol Gloff; Gary Connor; Julie Straub Embera NeuroTherapeutics and Indiana University Abstract: Background: No pharmaceutical treatments are currently available for cocaine use disorder, and treatments for tobacco use disorder are effective 25 % of the time at best. EMB-001 is a combination of two FDA-approved drugs: metyrapone, a cortisol synthesis inhibitor, and oxazepam, a benzodiazepine. Metyrapone is approved for one day only as a test; oxazepam is approved for acute and chronic treatment of anxiety. We hypothesized that a combination of drugs working by different stressrelated mechanisms may be efficacious for the treatment of substance use disorders, at doses that minimize the safety/tolerability risks of each individual drug.
Methods:
We summarize preclinical and clinical data supporting the potential efficacy and safety of EMB-001 for the treatment of substance use disorders, including a pilot human study in cocaine-dependent subjects, and a recently completed Phase 1 combined single/multiple ascending dose safety and PK study. Results: EMB-001 reduced cocaine self-administration in rats at doses of each individual drug that were ineffective alone (Goeders, 2008) . EMB-001 also reduced nicotine self-administration in rats (Goeders, 2012) , and attenuated cocaine and methamphetamine cue reactivity in rats (Keller, 2013) . A pilot human study of EMB-001 in cocaine dependence (Kablinger, 2012) showed a significant reduction in cocaine use and EMB-001 was generally well-tolerated. A new Phase 1 safety and PK study revealed EMB-001 to be well tolerated with no new safety signals identified. These safety results are generally consistent with 5 other published studies (O Dwyer 1995; Murphy 1998; Eriksson, 2001; Jahn, 2004; Rogoz 2004) . PK results from this new study suggest twice-daily dosing may provide appropriate duration of exposure for efficacy.
Conclusions: EMB-001 is effective in several animal models of drug addiction. A pilot human study suggested efficacy in cocaine-dependent subjects, and good tolerability. New data from a Phase 1 study extend the safety and tolerability findings and PK support BID dosing. EMB-001 has potential to treat cocaine and methamphetamine use disorders, for which no FDAapproved treatments exist. It also has potential for tobacco use disorder, for which a large unmet need and limited treatment option exist. Abstract: AZD3293 is a novel, potent, and selective brainpermeable human β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor in development for the treatment of Alzheimer s disease. The relative bioavailability of AZD3293 was investigated following administration of 2 tablet formulations versus an oral solution. Basic pharmacokinetic (PK) parameters for AZD3293 and its active metabolite (AZ13569724) were also evaluated. This phase I, open-label, randomized, 3-period, crossover study (NCT02039180) involved healthy male and nonfertile women aged 18-55 years. Sixteen patients were recruited to ensure that 12 completed all 3 treatments. All received a single dose of the 50-mg AZD3293 solution, tablet A, or tablet B on day 1 of each crossover period (days 1, 8, 15), followed by a 1-week washout period. Thirteen enrolled patients were men and 3 were women (mean ± SD age 39.3 ± 9.89 years); 14 completed the study. Relative bioavailability based on AZD3293 area under the curve 0 -geometric mean ratio versus oral solution was as follows [AQ1]: tablet A = 1.052 [90 % confidence interval (CI) 1.001-1.106); tablet B = 1.040 (90 % CI 0.989-1.093). The 90 % CI for geometric mean ratios of tablet A or tablet B versus oral solution were completely contained within the equivalence boundaries for all other PK parameters for both AZD3293 and AZ13569724. Plasma AZD3293 concentration time profiles were similar for all 3 formulations. AZD3293 concentrations were above the lower limit of quantification for all time points through to 72 h postdose. Six adverse events were reported by 6 patients (37.5 %); all were assessed as mild. Adverse events for tablet A were upper respiratory tract infection, headache, and dry skin [n = 1 each (6.3 %)]; for tablet B were headache [n = 1 (6.3 %)]; and for oral solution were dizziness and dry skin [n = 1 each (6.3 %)]. There were no clinically significant changes in clinical laboratory or vital sign evaluations. GastroPlus modeling predicted negligible impact of gastric pH changes on PK (up to pH 7.4). Both tablet formulations met the bioequivalence criteria when compared with the oral solution. Plasma AZD3293 and AZ13569724 concentrations were similar for all 3 formulations across all time points, suggesting they do not differ in a clinically meaningful manner. A 50-mg AZD3293 dose was well tolerated when administered as an oral solution or either tablet formulation. ***
